Tyler D. Bold

1.4k total citations
28 papers, 611 citations indexed

About

Tyler D. Bold is a scholar working on Infectious Diseases, Immunology and Epidemiology. According to data from OpenAlex, Tyler D. Bold has authored 28 papers receiving a total of 611 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Infectious Diseases, 11 papers in Immunology and 7 papers in Epidemiology. Recurrent topics in Tyler D. Bold's work include SARS-CoV-2 and COVID-19 Research (11 papers), Tuberculosis Research and Epidemiology (9 papers) and COVID-19 Clinical Research Studies (9 papers). Tyler D. Bold is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (11 papers), Tuberculosis Research and Epidemiology (9 papers) and COVID-19 Clinical Research Studies (9 papers). Tyler D. Bold collaborates with scholars based in United States, United Kingdom and Uganda. Tyler D. Bold's co-authors include J. Ernst, Andrea J. Wolf, Niaz Banaei, Ryan A. Langlois, Phillip A. Newmark, Ricardo M. Zayas, Joshua M. Thiede, Vineet D. Menachery, William E. Matchett and Marc K. Jenkins and has published in prestigious journals such as Nature Communications, The Journal of Immunology and Clinical Infectious Diseases.

In The Last Decade

Tyler D. Bold

24 papers receiving 604 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tyler D. Bold United States 11 407 227 189 147 59 28 611
Cecily C. Midkiff United States 16 337 0.8× 144 0.6× 210 1.1× 116 0.8× 46 0.8× 26 609
Åsa Hidmark Germany 14 239 0.6× 266 1.2× 87 0.5× 106 0.7× 40 0.7× 23 605
Martial Jaume France 12 570 1.4× 224 1.0× 128 0.7× 127 0.9× 28 0.5× 14 865
Izumi Kimura Japan 9 410 1.0× 182 0.8× 87 0.5× 146 1.0× 66 1.1× 18 697
Chuan Song China 10 197 0.5× 64 0.3× 111 0.6× 130 0.9× 58 1.0× 37 444
Longding Liu China 17 398 1.0× 159 0.7× 198 1.0× 259 1.8× 12 0.2× 60 821
Patricio Doldan Germany 6 439 1.1× 150 0.7× 105 0.6× 133 0.9× 10 0.2× 11 610
Ethan J. Fritch United States 9 503 1.2× 146 0.6× 111 0.6× 351 2.4× 59 1.0× 11 966
David Eduardo Meza-Sánchez Mexico 12 238 0.6× 199 0.9× 61 0.3× 182 1.2× 27 0.5× 23 525
Chris Mok Hong Kong 9 223 0.5× 173 0.8× 180 1.0× 159 1.1× 7 0.1× 9 501

Countries citing papers authored by Tyler D. Bold

Since Specialization
Citations

This map shows the geographic impact of Tyler D. Bold's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tyler D. Bold with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tyler D. Bold more than expected).

Fields of papers citing papers by Tyler D. Bold

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tyler D. Bold. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tyler D. Bold. The network helps show where Tyler D. Bold may publish in the future.

Co-authorship network of co-authors of Tyler D. Bold

This figure shows the co-authorship network connecting the top 25 collaborators of Tyler D. Bold. A scholar is included among the top collaborators of Tyler D. Bold based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tyler D. Bold. Tyler D. Bold is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Thiede, Joshua M., Nicholas N. Jarjour, Venkatramana D. Krishna, et al.. (2024). Human ACE2 Gene Replacement Mice Support SARS-CoV-2 Viral Replication and Nonlethal Disease Progression. ImmunoHorizons. 8(9). 712–720. 1 indexed citations
3.
Xu, Yingzheng, Michael T. Patterson, Adeline Bertola, et al.. (2024). Adrenal gland macrophages regulate glucocorticoid production through Trem2 and TGF-β. JCI Insight. 9(14). 6 indexed citations
4.
Broedlow, Courtney A., Candace Guerrero, Tyler D. Bold, et al.. (2024). SARS-CoV-2 infection is associated with intestinal permeability, systemic inflammation, and microbial dysbiosis in hospitalized patients. Microbiology Spectrum. 12(11). e0068024–e0068024. 6 indexed citations
5.
Thiede, Joshua M., David K. Meyerholz, Kenneth Ssebambulidde, et al.. (2023). Recently activated CD4 T cells in tuberculosis express OX40 as a target for host-directed immunotherapy. Nature Communications. 14(1). 8423–8423. 6 indexed citations
6.
Bold, Tyler D.. (2023). A new hope; the M. tuberculosis strikes back. Cell Host & Microbe. 31(3). 321–322.
7.
Patterson, Michael T., Maria Firulyova, Yingzheng Xu, et al.. (2023). Trem2 promotes foamy macrophage lipid uptake and survival in atherosclerosis. Nature Cardiovascular Research. 2(11). 1015–1031. 73 indexed citations
8.
Pape, Kathryn A., William E. Matchett, Amanda J. Kabage, et al.. (2022). Boosting corrects a memory B cell defect in SARS-CoV-2 mRNA–vaccinated patients with inflammatory bowel disease. JCI Insight. 7(12). 2 indexed citations
9.
Fiege, Jessica K., Joshua M. Thiede, William E. Matchett, et al.. (2021). Single cell resolution of SARS-CoV-2 tropism, antiviral responses, and susceptibility to therapies in primary human airway epithelium. PLoS Pathogens. 17(1). e1009292–e1009292. 47 indexed citations
10.
Matchett, William E., Vineet Joag, J. Michael Stolley, et al.. (2021). Cutting Edge: Nucleocapsid Vaccine Elicits Spike-Independent SARS-CoV-2 Protective Immunity. The Journal of Immunology. 207(2). 376–379. 102 indexed citations
11.
Thomas, Stefani N., Kathryn A. Pape, Jennifer M. Peters, et al.. (2021). Initial determination of COVID-19 seroprevalence among outpatients and healthcare workers in Minnesota using a novel SARS-CoV-2 total antibody ELISA. Clinical Biochemistry. 90. 15–22. 11 indexed citations
12.
Puskarich, Michael A., Nathan W. Cummins, Nicholas E. Ingraham, et al.. (2021). A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19. EClinicalMedicine. 37. 100957–100957. 49 indexed citations
13.
Gniadek, Thomas J., Joshua M. Thiede, William E. Matchett, et al.. (2020). SARS‐CoV‐2 neutralization and serology testing of COVID‐19 convalescent plasma from donors with nonsevere disease. Transfusion. 61(1). 17–23. 17 indexed citations
14.
Vedula, Rahul S., Matthew P. Cheng, Dimitrios Farmakiotis, et al.. (2020). Somatic GATA2 mutations define a subgroup of myeloid malignancy patients at high risk for invasive fungal disease. Blood Advances. 5(1). 54–60. 10 indexed citations
15.
Cheng, Matthew P., Tyler D. Bold, Isaac H. Solomon, et al.. (2019). Use of triazoles for the treatment of invasive aspergillosis: A three‐year cohort analysis. Mycoses. 63(1). 58–64. 10 indexed citations
16.
Cheng, Matthew P., Amanda E. Kusztos, Tyler D. Bold, et al.. (2019). Risk of Latent Tuberculosis Reactivation After Hematopoietic cell Transplantation. Clinical Infectious Diseases. 69(5). 869–872. 14 indexed citations
17.
Bold, Tyler D., et al.. (2012). Impaired Fitness of Mycobacterium africanum Despite Secretion of ESAT-6. The Journal of Infectious Diseases. 205(6). 984–990. 30 indexed citations
18.
Bold, Tyler D. & J. Ernst. (2012). CD4+ T Cell-Dependent IFN-γ Production by CD8+ Effector T Cells in Mycobacterium tuberculosis Infection. The Journal of Immunology. 189(5). 2530–2536. 50 indexed citations
19.
Bold, Tyler D., Niaz Banaei, Andrea J. Wolf, & J. Ernst. (2011). Suboptimal Activation of Antigen-Specific CD4+ Effector Cells Enables Persistence of M. tuberculosis In Vivo. PLoS Pathogens. 7(5). e1002063–e1002063. 117 indexed citations
20.
Zayas, Ricardo M., Tyler D. Bold, & Phillip A. Newmark. (2005). Spliced-Leader trans-Splicing in Freshwater Planarians. Molecular Biology and Evolution. 22(10). 2048–2054. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cecily C. Midkiff Breakdown of academic impact, for papers by Åsa Hidmark Breakdown of academic impact, for papers by Martial Jaume Breakdown of academic impact, for papers by Izumi Kimura Breakdown of academic impact, for papers by Chuan Song Breakdown of academic impact, for papers by Longding Liu Breakdown of academic impact, for papers by Patricio Doldan Breakdown of academic impact, for papers by Ethan J. Fritch Breakdown of academic impact, for papers by David Eduardo Meza-Sánchez Breakdown of academic impact, for papers by Chris Mok
Rankless by CCL
2026